Rash and diarrhoea each resulted in dose reductions in 2% of patients, and resulted in study discontinuation in up to 1% of patients receiving Tarceva plus gemcitabine.
Nii lööbe kui kõhulahtisuse tõttu vähendati annust 2% patsientidest ning uuringu katkestas kuni 1% patsientidest, kes said Tarceva’ t pluss gemtsitabiini.